

LIPPINCOTT
WILLIAMS &
WILKINS



SPIRAL[®]
MANUAL

(英文原版)

Manual of Dermatologic Therapeutics

Sixth Edition

配英汉索引

皮肤病治疗学手册

Edited by
Kenneth A. Arndt
Kathryn E. Bowers



Lippincott Williams & Wilkins Inc. 授权

天津科技翻译出版公司出版

LIPPINCOTT
WILLIAMS &
WILKINS



SPIRAL[®]
MANUAL

(英文原版)


Manual of Dermatologic Therapeutics

Sixth Edition

配英汉索引

皮肤病治疗学手册

Edited by
Kenneth A. Arndt
Kathryn E. Bowers



Lippincott Williams & Wilkins Inc. 授权
天津科技翻译出版公司出版

Manual of Dermatologic Therapeutics With Essentials of Diagnosis

Sixth Edition

Kenneth A. Arndt, M.D.

SkinCare Physicians of Chestnut Hill
Chestnut Hill, Massachusetts
Clinical Professor of Dermatology
Harvard Medical School
Boston, Massachusetts

Adjunct Professor of Medicine (Dermatology)
Dartmouth Medical School
Hanover, New Hampshire

Kathryn E. Bowers, M.D.

Beth Israel Deaconess Medical Center
Dermatology Associates of Concord
Assistant Clinical Professor of Dermatology
Harvard Medical School
Boston, Massachusetts

In Collaboration with

Murad Alam, M.D.

Fellow in Dermatology
SkinCare Physicians of Chestnut Hill
Chestnut Hill, Massachusetts

Rachel Reynolds, M.D.

Instructor in Dermatology
Harvard Medical School
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Sandy Tsao, M.D.

Instructor in Dermatology
Harvard Medical School
Massachusetts General Hospital
Boston, Massachusetts



LIPPINCOTT WILLIAMS & WILKINS

A **Wolters Kluwer** Company

Philadelphia • Baltimore • New York • London
Buenos Aires • Hong Kong • Sydney • Tokyo

著作权合同登记号:图字:02-2002-97

图书在版编目(CIP)数据

皮肤病治疗学手册 = Manual of Dermatologic Therapeutics / (美)阿恩特(Arndt, K. A.), (美)鲍尔斯(Bowers, K. E.)编著. - 影印本. - 天津:天津科技翻译出版公司, 2003.1

(SPIRAL[®] MANUAL 系列丛书)

ISBN 7-5433-1612-9

I. 皮... II. ①阿... ②鲍... III. 皮肤病学:治疗学-手册-英文 IV. R751.05-62

中国版本图书馆 CIP 数据核字(2002)第 073105 号

Copyright © 2002 by Lippincott Williams & Wilkins Inc.

All rights reserved. This book is protected by copyright. No part of this book may be reproduced in any form or by any means, including photocopying, or utilized by any information storage and retrieval system without written permission from the copyright owner.

Reprint authorized by Lippincott Williams & Wilkins Inc. Reprint is authorized for sale in the People's Republic of China only.

授权单位: Lippincott Williams & Wilkins Inc.

出版: 天津科技翻译出版公司

出版人: 邢淑琴

地址: 天津市南开区白堤路 244 号

邮政编码: 300192

电话: 022-87893561

传真: 022-87892476

E-mail: tsttbc@public.tpt.tj.cn

印刷: 山东新华印刷厂临沂厂

发行: 全国新华书店

版本记录: 900×1168 32 开本 13.75 印张 400 千字

2003 年 1 月第 1 版 2003 年 1 月第 1 次印刷

定价: 36.00 元

(如发现印装问题, 可与出版社调换)

Acquisitions Editor: Beth Barry
Developmental Editor: Sonya L. Seigafuse
Production Service: Bermedica Production, Ltd.
Production Manager: Robert Pancotti
Manufacturing Manager: Colin J. Warnock
Cover Designer: Patricia Gast
Compositor: Circle Graphics, Inc.
Printer: R. R. Donnelley Crawfordsville

© 2002 by LIPPINCOTT WILLIAMS & WILKINS
530 Walnut Street
Philadelphia, PA 19106 USA
LWW.com

All rights reserved. This book is protected by copyright. No part of this book may be reproduced in any form or by any means, including photocopying, or utilized by any information storage and retrieval system without written permission from the copyright owner, except for brief quotations embodied in critical articles and reviews. Materials appearing in this book prepared by individuals as part of their official duties as U.S. government employees are not covered by the above-mentioned copyright.

Printed in the USA

Library of Congress Cataloging-in-Publication Data

Arndt, Kenneth A.

Manual of dermatologic therapeutics : with essentials of diagnosis / Kenneth A. Arndt, in collaboration with Kathryn E. Bowers, Murad Alam, Rachel Reynolds.—6th ed.
p. ; cm.

Includes bibliographical references and index.

ISBN 0-7817-2170-9 (spiral)

1. Dermatology—Handbooks, manuals, etc. 2. Skin—Diseases—Treatment—Handbooks, manuals, etc. I. Bowers, Kathryn E. II. Alam, Murad. III. Reynolds, Rachel. IV. Title.

[DNLM: 1. Skin Diseases—therapy—Handbooks. 2. Skin Diseases—diagnosis—Handbooks. 3. Skin Diseases—physiopathology—Handbooks. WR 39 A747m 2001]
RL74 .A75 2001
616.5—dc21

2001045087

Care has been taken to confirm the accuracy of the information presented and to describe generally accepted practices. However, the authors and publisher are not responsible for errors or omissions or for any consequences from application of the information in this book and make no warranty, expressed or implied, with respect to the currency, completeness, or accuracy of the contents of the publication. Application of this information in a particular situation remains the professional responsibility of the practitioner.

The authors and publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accordance with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new or infrequently employed drug.

Some drugs and medical devices presented in this publication have Food and Drug Administration (FDA) clearance for limited use in restricted research settings. It is the responsibility of the health care provider to ascertain the FDA status of each drug or device planned for use in their clinical practice.

10 9 8 7 6 5 4 3 2 1

To my family, with love: Anne, David, Jennifer,
Pablo, and Alexander.

KAA

To my mother and father.

KEB

PREFACE

The material in this manual was originally prepared in a less detailed form for use by physicians, nurses, and other health care personnel at the Harvard Community Health Plan. The reception given such practical therapeutic guidelines by clinicians of various specialties, by medical students at the Harvard Medical School, and by house officers at the Harvard teaching hospitals encouraged expansion to a more comprehensive work.

The first five editions of *Manual of Dermatologic Therapeutics* have been greeted enthusiastically. It is gratifying that such an approach to rational therapeutics has become widely adopted and that this information has been further disseminated through Spanish, Portuguese, French, Italian, Indonesian, Japanese, and Taiwanese editions.

The sixth edition has been significantly revised and rewritten in collaboration with Drs. Murad Alam, Rachel Reynolds, and Sandy Tsao. New and updated textual, reference, and illustrative material has been added.

The *Manual* presents up-to-date information on the pathophysiology, diagnosis, and therapy of common cutaneous disorders. Diagnostic procedures and surgical and photobiologic techniques are explained in both theoretical and practical terms. The pharmacology, structure, and optimal use of dermatologic medication are discussed in detail.

The first portion of the *Manual* is organized so that a disease is defined initially and its pathophysiology is discussed according to the problem-oriented record system. Each disease is then subdivided into subjective data (symptoms), objective data (clinical findings), assessment, and therapy sections. A sequence of therapeutic interventions and alternative approaches to treatment is emphasized. The remainder of the text is concerned with procedures, techniques, treatment principles, and discussion of the pharmacodynamics and usage of specific medications employed in treating cutaneous disease.

We hope that the sixth edition of the *Manual* is as helpful an educational and practical guide to therapeutics and disease management as have been the previous five.

Kenneth A. Arndt, M.D.
Kathryn E. Bowers, M.D.

CONTENTS 目 录

Preface 前言	xiii
-------------------------	------

I. COMMON DERMATOLOGIC DISEASES: DIAGNOSIS AND THERAPY 常见皮肤病: 诊断和治疗

1 Acne 痤疮	3
2 Alopecia Areata 簇状脱发	21
3 Aphthous Stomatitis (Canker Sores) 口疮性口炎(口溃疡)	26
4 Bacterial Skin Infections 皮肤细菌感染	32
5 Bites and Stings (Spiders, Snakes, Insects) 叮咬伤(蜘蛛、蛇、昆虫)	39
6 Burns 烧伤	46
7 Corns and Calluses 鸡眼和胼胝	49
8 Dermatitis (Eczema) 皮炎(湿疹)	52
Atopic Dermatitis 特应性皮炎	52
Circumscribed Chronic Dermatitis (Lichen Simplex Chronicus) 局限性慢性皮炎(神经性皮炎)	57
Contact Dermatitis 接触性皮炎	58
Hand Dermatitis 手皮炎	62
Nummular Dermatitis 钱币状皮炎	64
9 Diaper Rash 尿布疹	69
10 Drug Eruptions, Allergic 过敏性药疹	72
11 Dry Skin (Chapping, Xerosis) and Ichthyosis Vulgaris 皮肤干燥(皸裂干燥)和寻常鱼鳞病	77

12 Erythema Multiforme	
多形性红斑	80
13 Erythema Nodosum	
结节性红斑	85
14 Fungal Infections	
真菌感染	88
Candidiasis	
念珠菌病	88
Dermatophyte Infections	
皮真菌感染	91
Tinea Versicolor	
花斑癣	97
15 Herpes Simplex	
单纯疱疹	102
16 Herpes Zoster and Varicella	
带状疱疹和水痘	110
17 Hyperpigmentation and Hypopigmentation	
色素沉着过多和色素沉着不足	118
18 Immunocompromised Patients: HIV-and Non-HIV-Positive	
免疫受损的病人: HIV 阳性和非 HIV 阳性	125
19 Infestations: Pediculosis, Scabies, and Ticks	
寄生: 虱病、疥疮和蜱	136
20 Intertrigo	
擦烂	148
21 Keloids and Hypertrophic Scars	
疤痕疙瘩和肥大性疤痕	150
22 Keratoses	
角化病	154
23 Milia	
粟粒疹	160
24 Molluscum Contagiosum	
传染性软疣	161
25 Pityriasis Rosea	
玫瑰糠疹	164
26 Pruritus	
瘙痒	166
27 Psoriasis	
银屑病	173
28 Rosacea and Perioral (Periorificial) Dermatitis	
酒渣鼻和口周皮炎	185
29 Seborrheic Dermatitis and Dandruff	
皮脂溢性皮炎和头皮屑	192

30	Sexually Transmitted Diseases (STDs)	
	性传播疾病(STDs)	196
	Genital Ulcer Disease	
	生殖器溃疡病	196
	Urethritis, Cervicitis, and/or Vaginitis	
	尿道炎、宫颈炎和(或)阴道炎	202
	Infestations	
	感染	207
	Other Viral Infections	
	其他病毒感染	207
	Other Diseases	
	其他疾病	207
31	Skin Cancer	
	皮肤癌	209
32	Skin Tags	
	皮赘	220
33	Sun Reactions and Sun Protection	
	日光反应和防晒	221
34	Urticaria	
	荨麻疹	230
35	Vascular Neoplasms and Malformations	
	血管瘤和畸形	236
36	Warts	
	疣	241

II. PROCEDURES AND TECHNIQUES 操作方法和技术

37	Operative Procedures	
	手术方法	255
	Biopsy	
	活组织检查	255
	Curettage	
	刮除术	257
	Electrosurgery	
	电外科	259
	Cryosurgery	
	冷冻外科	261
38	Diagnostic and Therapeutic Techniques	
	诊断和治疗技术	266
	Cytologic Smears	
	细胞学涂片	266
	Fungal Scraping and Culture	

真菌刮片和培养	266
Wood's Light Examination	
伍德光检查	268
Patch Testing	
斑点试验	269
Ultraviolet Light Therapy	
紫外光治疗	270

III. TREATMENT PRINCIPLES AND FORMULARY 治疗原则和处方集

39 Treatment Principles

治疗原则	277
Dermatologic Prescriptions and Drug Costs	
皮肤病学处方和药物花费	277
Types of Topical Medications	
局部用药物类型	277
Amount to Dispense	
用药量	279
General Principles of Normal Skin Care	
正常皮肤护理的一般原则	279

40 Formulary

处方集	284
Acne Preparations	
痤疮制剂	284
Anesthetics for Topical Administration	
表面处理麻醉药	291
Local Anesthetics	
局部麻醉药	292
Antihistamines	
抗组胺药	295
Antiinfective Agents	
抗感染因子	302
Antibacterial and Antiseptic Agents, Topical	
表面抗菌和防腐因子	302
Antifungal Agents	
抗真菌因子	308
Antiviral Agents	
抗病毒因子	322
Scabicides and Pediculicides	
杀疥螨药和灭虱药	324
Miscellaneous Agents	
各种各样因子	327

Antiinflammatory Agents	
抗炎因子	329
Topical and Intralesional Corticosteroids	
局部和损伤表面用皮质类固醇	329
Systemic Corticosteroids	
全身用皮质类固醇	338
Antiperspirants and Medications Used in the Treatment of	
Hyperhidrosis	
治疗多汗症使用的止汗药和药物治疗	343
Antipruritic and External Analgesic Agents	
止痒药和外用止痛药	345
Cleansing Agents	
清洁剂	349
Cosmetics and Covering Agents	
化妆品和遮盖剂	351
Depilatories and Removal of Excessive Hair	
脱毛剂和去毛	352
Dermatologic Topical Preparations and Vehicles	
皮肤病局部制剂和赋形剂	354
Insect Repellents	
驱虫药	358
Keratolytic, Cytotoxic, and Destructive Agents	
角质松解剂、细胞毒素和破坏药	359
Pigmenting and Depigmenting Agents, Sunscreens	
着色剂、脱色剂和遮光剂	367
Wet Dressings, Baths, Astringents	
湿敷剂、药浴和收敛剂	370
Wound Dressings	
外伤用敷料	372

Appendices 附录

A. Foundations, Institutes, and Support Groups	
基金会、研究院和支持组织	375
B. Dermatology Web Sites	
皮肤病学网址	380
英汉索引	381

**I. COMMON DERMATOLOGIC DISEASES:
DIAGNOSIS AND THERAPY**

1. ACNE

- I. **Definition and pathophysiology.** Acne, a very common, self-limited, multifactorial disorder involving the sebaceous follicles, is usually first noted in the teenage years. Lesions may begin as early as ages 8 to 10 years at *sebarche*, which in girls may precede menarche by more than a year. Prevalence increases steadily throughout adolescence *and then decreases in adulthood*. Though girls often develop acne at a younger age than boys, severe disease affects boys 10 times more frequently (up to 15% are involved). Patients with severe cystic acne often have a positive family history of the same.

Neonatal acne or cephalic pustulosis is self-limited and occurs during the first 2 weeks of life. Almost one in five newborns are affected by at least mild neonatal acne characterized by erythematous non-scarring papules on the face and neck. This disorder self-resolves in 1 to 3 months. Infantile acne (usually at age 3 to 6 months) includes persistent comedones and inflammatory lesions with an increased risk of scarring. Boys are more often affected than girls due to high testosterone levels from age 6 to 12 months. Individuals with infantile acne may have more severe teenage acne than their peers. One study implicated *Malassezia* organisms in infantile acne, and patients do respond to the imidazole creams. Some of these infants may eventually require isotretinoin (Accutane). Acne in mid-childhood may be a marker for adrenal or gonadal tumors.

A significant increase in adult acne has been observed over the last several decades. A recent study by Goulden found the prevalence of acne in a group aged 25 to 58 years to be 3% of men and 12% of women. Eighty-two percent of the individuals had experienced acne since teenage years and most did not see a decrease until after age 45. In another study by Goulden, 50% of patients with adult acne had a first-degree relative with post adolescent acne; one-third of the women had at least one symptom of hyperandrogenism and 37% of the entire group had failed a course of Accutane (1).

The principal factors involved in the pathogenesis of acne are increased sebum production, abnormal keratinization of the follicular epithelium, proliferation of *Propionibacterium acnes*, and inflammation. Severity of involvement often corresponds to the amount of sebum secreted; patients with severe acne usually will have large and active sebaceous glands with prominent follicular openings ("pores") and oily skin ("seborrhea"). However, there is much variation and overlap in sebum secretion between unaffected control subjects and acne patients, and no evidence has yet been found that sebum in acne patients differs qualitatively from that in normal persons.

Androgens are the only stimulus to sebaceous gland development and secretion. Lucky observed that adrenal maturation alone, with elevated dehydroepiandrosterone sulfate (DHEAS) levels, may be sufficient stimulus for sebum production in patients prone to cystic acne (1a). Early comedonal acne development is highly predictive of later, more severe disease. Early onset acne may be the first sign of an underlying hormonal abnormality, especially if there is an associated advanced bone age and early pubic hair development.

At puberty, hormonal stimuli lead to increased growth and development of sebaceous follicles. Female patients with severe acne or evidence of virilization often have abnormally high levels of circulating androgens. Several recent studies have demonstrated that many female patients with milder forms of acne and no evidence of virilization may still have ovarian and/or adrenal overproduction of androgens. In those patients with normal circulating levels of androgens, there is some evidence that suggests a heightened end-organ responsiveness of the sebaceous glands to androgenic stimulation. This heightened end-organ response results in increased conversion of testosterone to dihydrotestosterone (DHT) and other 5 alpha-reduced metabolites or suppressed follicular testosterone metabolism. Male acne patients tend to have higher levels of androstenedione, testosterone, free androgen index, and 11-deoxycortisol (2).

The enlarged gland secretes sebum into a dilated follicle that contains a disproportionately large quantity of normal cutaneous bacteria. Sebum contains free and esterified fatty acids as well as unsaponifiable lipid components. It is the free fatty acid (FFA) fraction of sebum, produced in the sebaceous follicle by the action of enzymes associated with the anaerobic diphtheroid *P. acnes* that acts as the primary irritating substance in inflammatory acne. As triglyceride levels rise, so does the population of *P. acnes*. In addition, *P. acnes* produces low-molecular-weight peptides, which act as chemoattractants for polymorphonuclear leukocytes. Patients with severe acne demonstrate cell-mediated immunity directed toward *P. acnes*, the severity of inflammation is proportional to the anti-*P. acnes* immunity. Other evidence for immune mechanisms includes the observation of complement component C3 in the walls of dermal blood vessels and the basement membrane zone of acne lesions. Attraction and killing of leukocytes by comedonal components, the resultant inflammatory cascade, and specific immunologic events probably all contribute to the final appearance of an inflammatory acne lesion.

Disordered shedding of the cells that line sebaceous follicles is another factor in the pathogenesis of acne lesions. Large numbers of desquamating horny cells tend to stick together rather than flow to the surface with sebum. Experimentally, follicular hyperkeratosis is induced by Interleukin 1 alpha (IL-1 alpha) and epidermal growth factors and isotretinoin inhibits this process. The resulting impacted lipid and keratin mass expands to fill the lumen and forms a solid plug in the dilated opening, becoming a closed comedo ("whitehead"). If this comedonal mass protrudes from the follicle, it is recognized as an open comedo ("blackhead"). Whether its dark color is due to oxidized lipid, melanin, or densely packed keratinocytes and bacteria, this plug most assuredly is *not* dirt. As hydrolytic enzymes released from polymorphonuclear leukocytes induce follicle walls to leak or rupture, sebum (with its irritant and chemoattractant factors), keratin, bacteria, and hair are released into the dermis and result in an inflammatory mass (papule, "pimple," pustule, nodule, cyst, and/or abscess).

Activation of the classic and alternative pathways of complement by *P. acnes* enhances the inflammation. Most acne papules or pustules result from rupture of an intrafollicular microcomedo rather than a visible one. Patients with large numbers of comedones usually have only small numbers of inflammatory lesions, whereas patients with severe cystic acne usually have few comedones. In adult life, the cells lining the follicle presumably become less susceptible to comedogenic materials. Spontaneous disappearance of acne also may be related to a decreased dermal reactivity to irritant substances.

As many as one-third of adult women are affected by a low-grade acneform eruption that may start *de novo* or merge imperceptibly with preexisting adolescent acne. The eruption may be induced by chronic exposure to comedogenic substances such as isopropyl myristate, cocoa butter, and fatty acids present in some creams and moisturizers, by androgenic stimuli from progestins present in some oral contraceptives, by recent cessation of oral contraceptives, or by unknown causes.

Acne may lead to pitted or hypertrophic scarring. If left alone, most inflammatory acne tends to disappear slowly in the early twenties in men and somewhat later in women. Adequate therapy will in all cases decrease its severity and may entirely suppress this disease. The link between acne and rosacea is unknown; some adult patients may have features of both diseases as their acne is decreasing and signs and symptoms of rosacea are increasing.

II. Subjective data

A. Patients' complaints may be related to inconspicuous lesions that nevertheless cause considerable social embarrassment. As with all medical and psychological conditions, the patient's perception of the severity of the problem is an important guide to treatment, and judgmental decisions by the physician about the severity of objective disease must be evaluated in this context.

A quality of life scale has been developed specifically for the acne patient. Respondents answer on a grade of 0 to 3 to what extent they have experienced each item.

1. Feeling self-conscious in the presence of others.
2. Decrease in your socialization with others.

3. Difficulties in your relationships with your spouse or partner.
 4. Difficulties in your relationships with your close friends.
 5. Difficulties in your relationships with your immediate family.
 6. Feeling like an "outcast" most of the time because of the effect of acne upon your appearance.
 7. People making fun of your appearance.
 8. Feeling rejected in a romantic relationship because of the effect of acne upon your appearance.
 9. Feeling rejected by your friends because of the effect of acne upon your appearance.
- B. Inflammatory lesions of acne may itch as they erupt and may be very painful on pressure.
 - C. Pustules and cysts often rupture spontaneously and drain a purulent and/or bloody but odorless discharge.

III. Objective data (See color insert.)

- A. **Noninflammatory lesions.** The initial lesion is the closed comedo; visible as a 1 to 2-mm white dot (whitehead) most easily seen when the skin is stretched. If follicle contents extrude, a 2 to 5-mm, dark-topped, open comedo (blackhead) results.
- B. **Inflammatory lesions.** Erythematous papules, pustules, cysts, and abscesses may be seen. Patients with cystic acne also tend to show "double," or polyporous, comedones, which result from prior inflammation during which epithelial tongues have caused fistulous links between neighboring sebaceous units. Acne lesions are seen primarily on the face, but the neck, chest, shoulders, and back may be involved. One or more anatomic areas may be involved in any given patient, and the pattern of involvement, once present, tends to remain constant.
- C. The skin, scalp, and hair are frequently very oily.

IV. Assessment. Several points regarding etiology or therapy should be considered with each patient:

- A. Are endocrine factors important in this patient? Sudden onset of acne, treatment-resistant acne, and acne associated with signs of androgenism should lead one to suspect an endocrine abnormality.
 1. Are menstrual periods regular? Is there any hirsutism? (Stein-Leventhal syndrome, Cushing's syndrome, 21-hydroxylase deficiency, and other endocrinopathies are frequently accompanied by acne.) As many as 80% of women with acne may have polycystic ovaries. This disorder is defined by menstrual irregularities, acne, pelvic ultrasound imaging of subcapsular ovarian cysts, and an elevated luteinizing hormone (LH) to follicle stimulating hormone (FSH) ratio (a level greater than 2 to 3 is suggestive). The testosterone elevations are modest in the range of 80 ng/dl to 150 ng/dl.

Men and women with mild to severe cystic acne, especially those who do not respond to conventional therapy, may have elevated plasma-free testosterone and/or DHEAS levels. Hyperandrogenism is associated with acne, hirsutism, alopecia, and menstrual irregularities; other possible findings include infertility, deepening of the voice, increased libido, acanthosis nigricans, insulin resistance, type 2 diabetes, mellitus and dyslipidemia. DHEAS elevations above 8,000 ng/ml suggest the presence of an adrenal tumor; a range of 4,000 ng/ml to 8,000 ng/ml is indicative of congenital adrenal hyperplasia. Testosterone elevations point to an ovarian dysfunction, with levels of 150 nd/dl to 200 nd/dl suggesting an ovarian tumor. Oral contraceptives can mask an underlying endocrine disorder, so testing should be done 1 month after discontinuation of the hormones. Women may have high normal levels of DHEAS and testosterone and may benefit from hormonal therapy. Postmenopausal acne occurs in dark-complexioned women with previously oily skin, with the development of small closed comedones at the periphery of the face; unopposed adrenal androgens are the presumed cause.